Clinical trial
Pilot Study of Rituximab for the Treatment of Acute Immune Thrombocytopenic…
NCT00372892 · Hamilton Health Sciences Corporation, Other · Completed
Key facts
| NCT number | NCT00372892 |
|---|---|
| Title | Pilot Study of Rituximab for the Treatment of Acute Immune Thrombocytopenic Purpura (ITP) |
| Official title | A Randomized, Double Blind, Placebo Controlled Pilot Trial of Rituximab for Non-splenectomized Adults With Acute Immune Thrombocytopenic Purpura Receiving Standard Treatment (R-ITP) |
| Lead sponsor | Hamilton Health Sciences Corporation, Other |
| Collaborators | Hoffmann-La Roche Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Purpura, Thrombocytopenic, Idiopathic |
| Intervention type | Drug |
| Interventions | Rituximab, Placebo |
| Enrollment | 60 |
| Start date | Sep 1, 2006 |
| Primary completion | Dec 1, 2010 |
| Completion | Jun 1, 2011 |
| First posted | Sep 7, 2006 |
| Last update posted | Jun 7, 2012 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: